ArticleIndian journal of sexually transmitted diseases and AIDS
Drug-induced normoglycemic candidal balanoposthitis: A case series.
Article in Indian journal of sexually transmitted diseases and AIDS. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One therapeutic option to manage hyperglycemia is to increase renal glucose excretion by inhibiting sodium-glucose cotransporter-2 (SGLT2) glucose transport proteins. SGLT2 inhibitors (SGLT2i) represent a novel class of oral antidiabetic drugs which are associated with drug-induced glucosuria which can be associated with candidial balanoposthitis and genitourinary infections. Our report includes 10 patients. Their glycated hemoglobin (HbA1c) ranged between 7 and 10 before treatment with SGLT2i. They had one or more episodes of candidal balanoposthitis due to uncontrolled diabetes mellitus. 3 patients were on dapagliflozin 5 mg and 7 were on empagliflozin 10 mg. Their HbA1c after SGLT2i ranged from 5 to 5.6. No adverse effects like urinary tract infections were noted. All ten of them had recurrent candidal balanoposthitis and presumed that their sugar levels were under control. The anticipated association of SGLT2i and increased risk of genital infection is a major cause of concern for diabetologists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.